Status:
COMPLETED
Telmisartan in Mild to Moderate Hypertensive Patients
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy and tolerability of telmisartan, given once a day to patients with mild to moderate hypertension, as well as to assess the 24-hour blood pressure profile with ABPM
Eligibility Criteria
Inclusion
- Patients with blood pressure levels of 140/90 mm Hg or higher (confirmed on 2 consecutive visits), who were 18 years old and older, regardless of sex
Exclusion
- Suspected or known diagnosis of arterial hypertension with a secondary cause
- Women who were not using an effective method of contraception, or who were pregnant, or breast-feeding
- Systolic blood pressure \> 200 mm Hg or diastolic blood pressure \> 115 mm Hg
- Laboratory test values two fold above the upper normal limit
- Previous intolerance to angiotensin conversion enzyme inhibitors or angiotensin II blocker (AIIAR)
- New York Heart Association class III or IV heart failure
- History of stroke in the 6 months prior to entry into the study
- Uncontrolled type 2 diabetes mellitus, defined as fasting glucose levels \> 140 mg/dL on 3 consecutive assessments
- Patients who were included in another investigational drug study in the past 30 days
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT02260089
Start Date
March 1 2000
Last Update
October 9 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.